Iloprost
Top View
- 684Fm.3 Iloprost Infusion Protocol
- 1628.Full-Text.Pdf
- First Inhaled Treatment Approved for PAH
- Management of Antithrombotic Drugs in Association with Endoscopic
- Infusion of Iloprost, a Prostacyclin Analogue, for Treatment of Raynaud's Phenomenon in Systemic Sclerosis
- Iloprost Suppresses Connective Tissue Growth Factor Production in Fibroblasts and in the Skin of Scleroderma Patients
- Product Information
- Heparin-Induced Thrombocytopenia and Cardiac Surgery Jerrold H
- Reproductive Health Guideline Appendix 3 – Search Strategies
- Profile Profile Uses and Administration Adverse Effects And
- The Biology of Prostaglandins and Their Role As a Target for Allergic Airway Disease Therapy
- PDF (Guidelines for ATC Classification and DDD Assignment)
- Search Strategy Systematic Review of Effect of Statins and Antiplatelets On
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- Project SCYLLA
- Systemic Glucocorticoids in the Treatment of COVID-19 and Risks of Adverse Outcomes in COVID-19 Patients in the Primary and Secondary Care Setting
- Clinical Policy: Iloprost (Ventavis) Reference Number: CP.PHAR.193 Effective Date: 03/16 Coding Implications Last Review Date: 03/17 Revision Log
- Ventavis, INN-Iloprost